Human T-cell lymphotropic virus type I-associated adult T-cell leukemia: the Joseph Goldberger Clinical Investigator Lecture
Article Abstract:
Adult T-cell leukemia lymphoma (ATL) may be successfully treated with immunotherapy. ATL is a cancer involving T-cells caused by the retrovirus human T-cell lymphotropic virus type I (HTLV-I). Patients with ATL may have enlarged lymph nodes, liver and spleen, and experience skin, nervous system and lung disorders, along with severe immunosuppression. Conventional anticancer drugs have not proved effective in treating ATL. Research involving the role of interleukin-2 (IL-2) receptors in ATL led clinicians to try an immunotherapeutic approach. Since the IL-2 receptor alpha is only expressed by the abnormally proliferating T-cells, monoclonal antibodies directed toward this receptor were armed with a yttrium radioisotope and infused into an ATL patient. This patient received five infusions with the radiolabeled monoclonal antibody and experienced partial remission for two years, followed by 21 months of complete remission, still ongoing at the time of the report.
Publication Name: JAMA, The Journal of the American Medical Association
Subject: Health
ISSN: 0098-7484
Year: 1995
User Contributions:
Comment about this article or add new information about this topic:
The platelet, the patient, and periprocedural infarction during percutaneous transluminal coronary angioplasty
Article Abstract:
The drug abciximab appears to lower mortality rates in certain patients after coronary angioplasty but the drug is expensive and may not prevent re-stenosis. Coronary angioplasty is used to open clogged coronary arteries, but the arteries can become clogged again, a condition called re-stenosis. Abciximab blocks the aggregation of blood platelets, which may be involved in re-stenosis. A 1997 study found that patients who received abciximab during angioplasty had lower rates of death, heart attack and repeat angioplasty three years later. However, only patients at high risk of complications from angioplasty appear to benefit from abciximab.
Publication Name: JAMA, The Journal of the American Medical Association
Subject: Health
ISSN: 0098-7484
Year: 1997
User Contributions:
Comment about this article or add new information about this topic:
Effect of Omalizumab on Symptoms of Seasonal Allergic Rhinitis: A Randomized Controlled Trial. (Original Contribution)
Article Abstract:
A monoclonal antibody that blocks immunoglobulin E (IgE) may be effective in treating hay-fever, according to a study of 536 patients with moderate to severe hay-fever. The antibody is called omalizumab and was evaluated at dosages of 50, 150, and 300 milligrams (mg).
Publication Name: JAMA, The Journal of the American Medical Association
Subject: Health
ISSN: 0098-7484
Year: 2001
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: Recombinant human erythropoietin and renal anemia: molecular biology, clinical efficacy, and nervous system effects
- Abstracts: Severe thrombocytopenia associated with cocaine use. Thombotic complications of antithrombotic therapy: a paradox with implications for clinical practice
- Abstracts: A newly discovered human pneumovirus isolated from young children with respiratory tract disease. Europe to standardize bacterial research
- Abstracts: Breast cancer therapy - the price of success. Mind matters -- group therapy and survival in breast cancer. The effect of group psychosocial support on survival in metastatic breast cancer
- Abstracts: Seroprevalence of antibody against poliovirus in inner-city preschool children: implications for vaccination policy in the United States